Kashiv Looks To Phase III Trial On Orencia Biosimilar, Setting Up Reddy’s Race
Privately-Held Firm Sees Abatacept Candidate Meet Primary Endpoints In Phase I
Kashiv Biosciences has followed on swiftly from positive noises from Dr Reddy’s Laboratories, disclosing that its proposed biosimilar to the hard-to-manufacture costimulation modulator Orencia was a success in Phase I trials.
